The relevance of P2Y₁₂-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up

• References

• 1 Fontana P, Dupont A, Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-995.
• 2 Rudez G, Bouman HJ, van Werkum JW. et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009; 02: 515-521.
• 3 Bouman HJ, van Werkum JW, Rudez G. et al. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thromb Haemost 2010; 103: 379-386.
• 4 Breet NJ, van Werkum JW, Bouman HJ. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
• 5 TIMI Study Group.. Definitions used in TIMI-trials. Available at: http://www.timi.org/wp-content/uploads/2010/10/TIMI-Definitions.pdf Accessed April 12th 2011.
• 6 Cutlip DE, Windecker S, Mehran R. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
• 7 Harmsze AM, Robijns K, van Werkum JW. et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010; 103: 920-925.
• 8 Sarafoff N, Neumann L, Morath T. et al. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161: 605-610.
• 9 Bates ER, Lau WC, Angiolillo DJ.. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-1263.
• 10 Patrono C.. The P2Y12 receptor: no active metabolite, no party. Nat Rev Cardiol 2009; 06: 271-272.
• 11 Shuldiner AR, O'Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009; 302: 849-857.
• 12 Bouman HJ, Schomig E, van Werkum JW. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110-116.
• 13 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
• 14 Gurbel PA, Kereiakes DJ, Tantry US.. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother 2010; 11: 2251-2259.
• 15 Jakubowski JA, Winters KJ, Naganuma H. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.